Objectives:
Discuss key recommendations from the 2022 ADA Standards of Medical Care in Diabetes related to use of non-insulin glucose-lowering therapies;
Review key safety, tolerability, and risk-mitigation strategies to consider with non-insulin glucose-lowering therapies; and
Emphasize the importance of diabetes self-management education to optimize use of non-insulin therapies.
Speaker:
Richard S. Beaser, MD
Medical Director of Continuing Medical Education
Senior Strategic Advisor, Education Programs. Joslin Diabetes Center
Associate Professor of Medicine, Harvard Medical School